ERBB2 and invasive breast carcinoma: It is well established that the Oncotype Dx RS can be used to quantify the risk of distant recurrence in patients with stages I and II ER+, Her2 negative, and LN negative invasive breast cancer who will be treated with tamoxifen [1].